Harm0nicsa, it seems like your rigorous "dcf valuation & technical momentum assessments mechanism" has diverted your perception from the simplicity of the obvious.
AGN has been one of the top plays in the unique hybrid-pharma sector. It has earned it's 26X P/E; delivering 5 years, of 14 percent EPS growth and it's forward P/E of 18-20X will keep it an attractive buy to most prudent investors.
Your macro economic prognostication is extremely bearish and misses the mark on the current econ-environment.
May I suggest you expand your model to include; AGN's mgmt, products and performance and perhaps you will gain greater insight.